Target intelligence / Profile preview

Adhesion molecule with Ig-like domain 3 (AMIGO3)

Target
AMIGO3
Molecular classification
Cell adhesion molecule (CAM), Immunoglobulin superfamily (contains Ig-like domains), Leucine-rich repeat (LRR) protein family
01

Overview

Adhesion molecule with Ig-like domain 3 (AMIGO3) is a membrane protein of the immunoglobulin superfamily, containing leucine-rich repeat motifs and Ig-like domains, widely expressed in astrocytes, oligodendrocytes, and neurons. Its main biological functions are mediating heterophilic cell-cell adhesion, modulating synaptic plasticity, and inhibiting axon regeneration and myelin production after CNS damage via the ROCK/RhoA signaling pathway. AMIGO3 is upregulated after neural injury and is considered a therapeutic target for demyelinating conditions and abnormal neural circuitry in diseases such as epilepsy and spinal cord injury. Antagonism of AMIGO3 has shown promise in preclinical models for improving myelin repair and neural regeneration.

Other names
Amphoterin-induced protein 3AMIGO3ALI3KIAA1851UNQ6084/PRO20089AMIGO-3Alivin-3amphoterin-induced gene and open reading frame 3amphoterin-induced gene and ORF 3
02

Mechanism of action

Inhibition of AMIGO3 can promote myelin regeneration and axon outgrowth, likely via ROCK/RhoA pathway modulation. It has potential to substitute for LINGO1 in the Nogo receptor complex, mediating myelin-induced axon outgrowth inhibition.

03

Biological functions

Heterophilic cell-cell adhesionSignal transduction via its intracellular domainRegulation of synapse assemblyInhibition of axon outgrowth and myelin productionParticipation in ROCK/RhoA signaling pathway
04

Disease associations

Neurodegenerative disease (potentially in demyelinating diseases and epileptogenesis)Mirror Movements 1 (gene-disease association in GeneCards)CNS injury (spinal cord injury, seizure-related brain damage)
05

Safety considerations

Unclear; as AMIGO3-targeted therapies are largely experimental, safety profile not establishedPotential concerns include disruption of normal neural circuit formation, or off-target effects on synapse integrity and function
06

Biomarkers

AMIGO3 protein expression in brain (upregulated after seizure/SC)myelin basic protein (MBP) levels as a marker for therapeutic effect in demyelinating conditions

Beyond the preview

Go deeper on Adhesion molecule with Ig-like domain 3 (AMIGO3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Adhesion molecule with Ig-like domain 3 (AMIGO3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call